SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Ella Fitzgerald

PatientElla Fitzgerald
Date of birth1956-04-25
IdentifiersMRN HR-ML029-SYN; SSN (made up) 000-29-3640
Document date2026-08-10
AuthorOdessa Whitlow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review: A1c, lipids, walking program, eye treatment, and foot care. [S]

History of Present Illness

Ms. Fitzgerald returns three months after her first visit, after a two-week run of concerts. She completed ten weeks of the supervised exercise program and walked to the home plan on tour; she can now walk about three blocks before calf pain, and the pain eases faster. She has had three right-eye injections, and her right eye is clearer. The podiatrist pared her calluses and she now performs in low-heeled custom stage shoes. Her glucose monitor shows time in range 66% and time below 70 mg/dL 0.8%, with no reading below 54 mg/dL; she ate before every late show. She has had no bleeding on rivaroxaban and aspirin. Her hepatitis C screening test was negative. She would like to know whether anything else can help her legs and her glucose. [S]

ElementDetail
GlucoseTime in range 66%; time below 70 mg/dL 0.8%; none below 54
WalkingAbout three blocks, from one and a half
Eye treatmentThree right-eye injections; vision clearer
FeetCalluses pared; low-heeled stage shoes
BleedingNone

Review of Systems

SystemResultFinding
CardiovascularPositiveCalf pain after about three blocks; no chest pain or rest pain
EyesPositiveRight-eye blur better
HematologicNegativeNo bruising, nosebleeds, or blood in the urine or stool
IntegumentaryNegativeNo foot sores

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with breakfast and the evening mealOral route2016-03-01activeS
Glipizide 10 mg oral tablet, one tablet by mouth twice daily before mealsOne tablet by mouth twice daily before breakfast and the evening mealOral route2021-09-01 to 2026-05-11completedS
Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime30 units at bedtimeSubcutaneous route2023-04-01 to 2026-05-11completedS
Insulin glargine 100 units/mL pen, 24 units under the skin each morning24 units each morning, at the same clock time on tour, with written time-zone adjustmentsSubcutaneous route2026-05-11activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02 to 2026-05-11completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgeryOral route2026-05-11activeS
Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucoseOne spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911Nasal route2026-05-11activeS
Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mgOne tablet by mouth twice daily, with aspirin 81 mg once dailyOral route2026-05-26activeS
Semaglutide 0.25 mg under the skin once weekly for four weeks0.25 mg once weekly on the same day each week for four weeksSubcutaneous route2026-08-10 to 2026-09-07completedS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-08-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-10Body height165cmS
2026-08-10Body weight82.1kgS
2026-08-10Body mass index (BMI) [Ratio]30.2kg/m2S
2026-08-10Systolic blood pressure122mm[Hg]S
2026-08-10Diastolic blood pressure68mm[Hg]S
2026-08-10Heart rate62/minS
2026-08-10Respiratory rate16/minS
2026-08-10Body temperature36.6CelS
2026-08-10Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-10Hemoglobin A1c/Hemoglobin.total in Blood7.6%Below 5.7% is normal; her individualized goal is below 7.5%HighS
2026-08-10Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-08-10Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-08-10Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.59-1.04 mg/dLNormalS
2026-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M64mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-10Cholesterol [Mass/volume] in Serum or Plasma128mg/dL<=199 mg/dLNormalS
2026-08-10Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation64mg/dLHer goal with coronary and peripheral artery disease is below 55 mg/dLNormalS
2026-08-10Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=50 mg/dLLowS
2026-08-10Triglyceride [Mass/volume] in Serum or Plasma112mg/dL<=149 mg/dLNormalS
2026-08-10Visual acuity best corrected Right eye by ETDRS eye chart71{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50LowS
2026-08-10Visual acuity best corrected Left eye by ETDRS eye chart81{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50NormalS

Physical Exam

Vital signs recorded on 2026-08-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 82.1 kg, BMI 30.2; blood pressure 122/68, pulse 62
FeetSkin intact; small calluses; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; shoes fit well
EyesBest-corrected acuity 71 letters right and 81 letters left

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complicationsactiveconfirmed E11.51S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.
Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problemsactiveconfirmed E11.3311S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.
Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgeryactiveconfirmed I25.10S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHemoglobin A1cEvery three months when not at goal or after a change; every six months at goalCompleted today7.6%, from 8.6%
Medication safetyContinuous glucose monitor review: time in range and time below rangeEvery visitCompleted todayTime in range 66%; time below 70 mg/dL 0.8%; none below 54 mg/dL
Medication safetyHypoglycemia events, show-day plan, and glucagonEvery visitCompleted todayNo level 2 or 3 lows; ate before every late show; glucagon unused
Medication safetyEmpagliflozin safety: genital infection, volume, and sick-day rulesAt the start and every visitCompleted todayNo genital infection; no dizziness on stage
LaboratoryCreatinine, eGFR, and potassiumWithin three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban reviewCompleted todayCreatinine 0.96 mg/dL, eGFR 64, potassium 4.6, sodium 140 mmol/L
LaboratoryUrine albumin-creatinine ratioYearlyUp to date18 mg/g at intake
LaboratoryLipid panel4 to 12 weeks after a statin or other lipid-lowering change, then yearlyDeferredDue 4 to 12 weeks after atorvastatin was raised; drawn today at 13 weeks, one week late, because she was on tour. LDL 64 mg/dL, above goal; no harm from the one-week delay. Corrective action: lipid tests after any change are booked before she leaves on tour
ExaminationFoot inspection, protective sensation, and pulsesEvery visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six monthsCompleted todayNo ulcer; protective sensation intact; podiatry seen in June, next visit in September
ImagingAnkle-brachial and toe-brachial indicesAt diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptomsUp to dateRepeat with duplex at the six-month vascular review
ExaminationWalking distance and claudication symptomsEvery visitCompleted todayAbout three blocks before calf pain, from one and a half
Self-managementSupervised exercise therapyThree times a week for twelve weeksCompleted todayTen of twelve weeks done; home plan followed on tour
ImagingRetinal examination and visual acuityWith each retina-clinic treatment while macular edema is treated; at least yearly in both eyesCompleted todayAcuity 71 letters right and 81 left; three injections; retina clinic told about semaglutide
ExaminationBlood pressureEvery visitCompleted today122/68 mmHg
ExaminationWeight and BMIEvery visitCompleted today82.1 kg, down 1.9 kg
Medication safetyBleeding on rivaroxaban and aspirinAt the start and every visitCompleted todayNo bleeding
Medication safetySemaglutide tolerance: nausea, appetite, and dose stepAt the start and each dose stepCompleted todayStarting today; nausea and dose steps explained
Self-managementAccess and equity: tour-date scheduling, video visits, large print, drug costsEvery visitCompleted todaySemaglutide cost checked with her Part D plan; next visit set before the autumn tour

Goal progress:

Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025)

Follow-up: Semaglutide dose step in four weeks, by video visit if she is touring. Podiatry in September. Review in eleven weeks with A1c, lipids, and kidney tests; zoster vaccine dose 1 at that visit. Next scheduled visit 2026-10-26: five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up. [S]